Join our daily newsletter At The Bell to receive exclusive market insights
- Lumos Diagnostics (LDX) receives authorisation to sell its COVID-19 rapid diagnostic test in Canada
- CoviDx gives healthcare providers results within 15 to 20 minutes, with a simple ‘yes or no’ answer
- The test will be available to qualified healthcare providers in Canada through Lumos’ Canadian distribution partners
- Lumos says the authorisation helps advance public health and safety in Canada and supports the continuity of commerce, tourism and education across the country
- On the market this afternoon, Lumos is up a slight 0.85 per cent to trade at 86 cents
Lumos Diagnostics (LDX) has received authorisation to sell and distribute its COVID-19 rapid test in Canada.
CoviDx is a point-of-care diagnostic test that uses individual pre-filled extraction reagent vials to make it easy to administer in any patient care setting. It also provides a simple ‘yes/no’ result.
CoviDx gives healthcare providers results within 15 to 20 minutes in cases of suspected COVID-19 or performing serial testing in patients without symptoms.
The test will be available to qualified healthcare providers in Canada through Lumos’ Canadian distribution partners.
Lumos CEO and President Rob Sambursky spoke on the authorisation in Canada.
“As SARS-CoV-2 continues to evolve, rapid point-of-care testing is a critical component of the Canadian public health response”, he said.
“Using CoviDx as part of routine testing and triage protocols can help advance public health and safety in Canada, while also supporting the important efforts underway to ensure the continuity of commerce, tourism and education across the country.”
On the market this afternoon, Lumos was up a slight 0.85 per cent to trade at 86 cents per share at 2:11 pm AEDT.
